Krystal Biotech Inc
For the period ended Mar 31, 2024. Filed May 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 6, 2024
KRYS$306.50+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows for the and
Condensed Consolidated Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| (in thousands) | 2024 | 2023 |
| Operating Activities | ||
| Net income (loss) | $932 | $(45,297) |
| Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities | ||
| Depreciation | 1,427 | 1,093 |
| Accretion on marketable securities | (802) | (606) |
| Amortization of operating lease right-of-use assets | 182 | 218 |
| Stock-based compensation expense, net | 9,299 | 10,437 |
| Realized gain on investments | (1,213) | (809) |
| Other, net | (238) | 1 |
| Changes in operating assets and liabilities | ||
| Accounts receivable | (4,427) | — |
| Inventory | (2,238) | — |
| Prepaid expenses and other current assets | (264) | (126) |
| Other non-current assets | 52 | (46) |
| Lease liability | (199) | (165) |
| Accounts payable | 727 | 107 |
| Accrued expenses and other current liabilities | (5,162) | (3,463) |
| Accrued rebates | 5,312 | — |
| Accrued litigation settlement | 12,500 | 12,500 |
| Net cash provided by (used in) operating activities | 15,888 | (26,156) |
| Investing Activities | ||
| Purchases of property and equipment | (1,260) | (5,381) |
| Purchases of investments | (88,335) | (145,576) |
| Maturities of investments | 63,615 | 154,520 |
| Net cash (used in) provided by investing activities | (25,980) | 3,563 |
| Financing Activities | ||
| Proceeds from exercise of stock options, net | 15,969 | 2,223 |
| Taxes paid for employee tax withholding related to restricted stock units | (4,181) | — |
| Taxes paid related to settlement of restricted stock awards | (1,205) | (749) |
| Net cash provided by financing activities | 10,583 | 1,474 |
| Effect of exchange rate changes on cash and cash equivalents | 187 | (36) |
| Net increase (decrease) in cash and cash equivalents | 678 | (21,155) |
| Cash and cash equivalents at beginning of period | 358,328 | 161,900 |
| Cash and cash equivalents at end of period | $359,006 | $140,745 |
| Supplemental Disclosures of Non-Cash Investing Activities | ||
| Unpaid purchases of property and equipment included in accounts payable and accrued expenses | $8,456 | $11,865 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.